Search Results

RemeGen Co., Ltd. (“RemeGen” or “the Company”) (9995.HK, SHA: 688331), a commercial-stage biotechnology company, showcased its innovation in the field of global cancer treatment at the American Society of Clinical Oncology Annual Meeting (ASCO 2024) held in Chicago from May 31-June 4, 2024.

RemeGen Co. Ltd., a commercial-stage biotechnology company, obtained Fast Track Designation by the United States Food and Drug Administration recently for its innovative BLyS/APRIL dual-target fusion protein drug, Telitacicept, independently developed by RemeGen for the treatment of patients with primary Sjögren’s syndrome.

RemeGen Co., Ltd. (“RemeGen” or “the Company”) (9995.HK, SHA: 688331), a commercial-stage biotechnology company, presented the results of the first-in-human, single-arm, open-label, multi-center Phase I/II study evaluating RC88 in patients with MSLN-expressing advanced solid tumors on June 3, at the American Society of Clinical Oncology Annual Meeting (ASCO 2024) held in Chicago from May 31-June 4, 2024.

RemeGen Co. Ltd., a commercial-stage biotechnology company, recently announced significant progress of Telitacicept, that two Phase III clinical trials in China for the treatment of IgA nephropathy and primary Sjögren’s syndrome have completed patient enrollments.

RemeGen Co. Ltd. (“RemeGen” or “the Company”) (9995.HK, SHA: 688331), a commercial-stage biotechnology company, has recently confirmed that under the 2023 simple renewal mechanism of China National Healthcare Security Administration (NHSA), on January 1, 2024, the updated National Reimbursement Drug List (NRDL) will continue to include Telitacicept (RC18) and Disitamab Vedotin (RC48) for the next two-year agreement.